vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $766.5M, roughly 1.5× SCANSOURCE, INC.). SCANSOURCE, INC. runs the higher net margin — 2.2% vs -24.1%, a 26.3% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 2.5%). Elanco Animal Health Inc produced more free cash flow last quarter ($46.0M vs $28.9M). Over the past eight quarters, SCANSOURCE, INC.'s revenue compounded faster (0.9% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
ELAN vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $766.5M |
| Net Profit | $-276.0M | $16.5M |
| Gross Margin | 51.5% | 13.4% |
| Operating Margin | -22.6% | 2.3% |
| Net Margin | -24.1% | 2.2% |
| Revenue YoY | 12.2% | 2.5% |
| Net Profit YoY | -3350.0% | -3.3% |
| EPS (diluted) | $-0.55 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $766.5M | ||
| Q3 25 | $1.1B | $739.6M | ||
| Q2 25 | $1.2B | $812.9M | ||
| Q1 25 | $1.2B | $704.8M | ||
| Q4 24 | $1.0B | $747.5M | ||
| Q3 24 | $1.0B | $775.6M | ||
| Q2 24 | $1.2B | $746.1M | ||
| Q1 24 | $1.2B | $752.6M |
| Q4 25 | $-276.0M | $16.5M | ||
| Q3 25 | $-34.0M | $19.9M | ||
| Q2 25 | $11.0M | $20.1M | ||
| Q1 25 | $67.0M | $17.4M | ||
| Q4 24 | $-8.0M | $17.1M | ||
| Q3 24 | $364.0M | $17.0M | ||
| Q2 24 | $-50.0M | $16.1M | ||
| Q1 24 | $32.0M | $12.8M |
| Q4 25 | 51.5% | 13.4% | ||
| Q3 25 | 53.4% | 14.5% | ||
| Q2 25 | 57.5% | 12.9% | ||
| Q1 25 | 57.3% | 14.2% | ||
| Q4 24 | 50.9% | 13.6% | ||
| Q3 24 | 52.2% | 13.1% | ||
| Q2 24 | 58.2% | 13.0% | ||
| Q1 24 | 57.3% | 12.6% |
| Q4 25 | -22.6% | 2.3% | ||
| Q3 25 | -4.4% | 3.5% | ||
| Q2 25 | 2.0% | 3.3% | ||
| Q1 25 | 5.0% | 3.2% | ||
| Q4 24 | -5.0% | 2.5% | ||
| Q3 24 | 54.3% | 2.3% | ||
| Q2 24 | -2.7% | 2.9% | ||
| Q1 24 | 1.0% | 2.3% |
| Q4 25 | -24.1% | 2.2% | ||
| Q3 25 | -3.0% | 2.7% | ||
| Q2 25 | 0.9% | 2.5% | ||
| Q1 25 | 5.6% | 2.5% | ||
| Q4 24 | -0.8% | 2.3% | ||
| Q3 24 | 35.3% | 2.2% | ||
| Q2 24 | -4.2% | 2.2% | ||
| Q1 24 | 2.7% | 1.7% |
| Q4 25 | $-0.55 | $0.75 | ||
| Q3 25 | $-0.07 | $0.89 | ||
| Q2 25 | $0.02 | $0.87 | ||
| Q1 25 | $0.13 | $0.74 | ||
| Q4 24 | $-0.01 | $0.70 | ||
| Q3 24 | $0.73 | $0.69 | ||
| Q2 24 | $-0.10 | $0.66 | ||
| Q1 24 | $0.06 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $83.5M |
| Total DebtLower is stronger | $3.9B | — |
| Stockholders' EquityBook value | $6.5B | $910.9M |
| Total Assets | $13.4B | $1.7B |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $545.0M | $83.5M | ||
| Q3 25 | $505.0M | $124.9M | ||
| Q2 25 | $539.0M | $126.2M | ||
| Q1 25 | $487.0M | $146.3M | ||
| Q4 24 | $468.0M | $110.5M | ||
| Q3 24 | $490.0M | $145.0M | ||
| Q2 24 | $416.0M | $185.5M | ||
| Q1 24 | $345.0M | $159.1M |
| Q4 25 | $3.9B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.8B | — |
| Q4 25 | $6.5B | $910.9M | ||
| Q3 25 | $6.7B | $914.0M | ||
| Q2 25 | $6.8B | $906.4M | ||
| Q1 25 | $6.4B | $901.7M | ||
| Q4 24 | $6.1B | $900.7M | ||
| Q3 24 | $6.5B | $920.9M | ||
| Q2 24 | $5.9B | $924.3M | ||
| Q1 24 | $6.1B | $944.1M |
| Q4 25 | $13.4B | $1.7B | ||
| Q3 25 | $13.6B | $1.7B | ||
| Q2 25 | $13.7B | $1.8B | ||
| Q1 25 | $12.9B | $1.7B | ||
| Q4 24 | $12.6B | $1.7B | ||
| Q3 24 | $13.3B | $1.8B | ||
| Q2 24 | $13.8B | $1.8B | ||
| Q1 24 | $14.0B | $1.8B |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — | ||
| Q1 24 | 0.95× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | $30.8M |
| Free Cash FlowOCF − Capex | $46.0M | $28.9M |
| FCF MarginFCF / Revenue | 4.0% | 3.8% |
| Capex IntensityCapex / Revenue | 5.4% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.0M | $30.8M | ||
| Q3 25 | $219.0M | $23.2M | ||
| Q2 25 | $237.0M | — | ||
| Q1 25 | $-4.0M | $66.1M | ||
| Q4 24 | $177.0M | $-6.2M | ||
| Q3 24 | $162.0M | $44.8M | ||
| Q2 24 | $200.0M | — | ||
| Q1 24 | $2.0M | $160.2M |
| Q4 25 | $46.0M | $28.9M | ||
| Q3 25 | $127.0M | $20.8M | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $-69.0M | $64.6M | ||
| Q4 24 | $130.0M | $-8.2M | ||
| Q3 24 | $120.0M | $42.5M | ||
| Q2 24 | $166.0M | — | ||
| Q1 24 | $-22.0M | $157.7M |
| Q4 25 | 4.0% | 3.8% | ||
| Q3 25 | 11.2% | 2.8% | ||
| Q2 25 | 14.5% | — | ||
| Q1 25 | -5.8% | 9.2% | ||
| Q4 24 | 12.7% | -1.1% | ||
| Q3 24 | 11.7% | 5.5% | ||
| Q2 24 | 14.0% | — | ||
| Q1 24 | -1.8% | 21.0% |
| Q4 25 | 5.4% | 0.3% | ||
| Q3 25 | 8.1% | 0.3% | ||
| Q2 25 | 4.6% | 0.3% | ||
| Q1 25 | 5.4% | 0.2% | ||
| Q4 24 | 4.6% | 0.3% | ||
| Q3 24 | 4.1% | 0.3% | ||
| Q2 24 | 2.9% | 0.2% | ||
| Q1 24 | 2.0% | 0.3% |
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | 21.55× | — | ||
| Q1 25 | -0.06× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | 0.45× | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.06× | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
